Total Testosterone: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Levels

What Total Testosterone Actually Measures

Total testosterone is the combined concentration of three fractions in serum: testosterone bound to sex-hormone-binding globulin (SHBG, approximately 44 to 65% of the total), testosterone loosely attached to albumin (30 to 40%), and the small free fraction (1 to 3%) that enters cells directly 1. Laboratories report all three fractions together as a single ng/dL value.

The free and albumin-bound fractions are collectively called "bioavailable testosterone." Because SHBG fluctuates with age, liver function, thyroid status, and obesity, total testosterone can appear normal while bioavailable testosterone is actually deficient. This is why HealthRX always orders SHBG alongside total testosterone for baseline evaluations.

Why the Assay Method Matters

Immunoassay-based total testosterone tests, which most commercial labs use, are accurate enough for male ranges but are unreliable at the low concentrations typical of women and children 2. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold-standard method and is mandatory for female and pediatric specimens according to the American Urology Association and the Endocrine Society 3.

Diurnal Variation and Specimen Timing

In men, total testosterone peaks between 7:00 and 10:00 a.m. And drops by 20 to 35% by afternoon 4. A single late-afternoon draw in a healthy man can fall below 300 ng/dL, mimicking hypogonadism. The Endocrine Society's 2018 clinical practice guideline specifies that diagnostic samples must be collected between 7:00 and 10:00 a.m. On at least two separate mornings before a diagnosis is made 3. Diurnal variation is less pronounced in older men and is not well-characterized in women.

Normal Total Testosterone Ranges in Men

The Endocrine Society defines male hypogonadism as a total testosterone consistently below 300 ng/dL, paired with symptoms such as low libido, fatigue, or loss of lean mass 3. The upper boundary of normal sits near 1,000 ng/dL in most U.S. Laboratory reference intervals.

Age-Stratified Reference Intervals

Total testosterone declines throughout adult male life. The Massachusetts Male Aging Study (N=1,709) documented a mean fall of 1.6% per year in total testosterone and 2 to 3% per year in free testosterone, independent of illness or medication 5. The following ranges reflect Harmonized Reference Intervals from the Endocrine Society's Testosterone Standardization Project 6:

| Age Group | Total Testosterone (ng/dL) | |---|---| | 19 to 39 years | 264 to 916 | | 40 to 59 years | 201 to 993 | | 60 to 79 years | 156 to 700 | | 80 years and older | 90 to 417 |

Values derived from the CDC-calibrated Harmonized Testosterone Standardization Project reference cohort 6.

What "Optimal" Means for Men

A normal range describes a statistical distribution in the population; an optimal range reflects the level associated with best clinical outcomes. The T Trials (N=790 men age 65+, baseline testosterone <275 ng/dL) found that raising total testosterone to 500 ng/dL or above improved sexual function, bone density, and anemia scores at 12 months 7. Longevity-medicine practitioners generally target 500 to 900 ng/dL for men on TRT, keeping free testosterone in the upper quartile of the normal range while monitoring hematocrit and PSA.

No randomized trial has established a hard upper boundary for safety in otherwise healthy men, but the Endocrine Society cautions against targeting levels above 1,000 ng/dL outside of specialist oversight 3.

Normal Total Testosterone Ranges in Women

Women produce testosterone primarily in the ovaries and adrenal glands. Total testosterone in reproductive-age women typically spans 15 to 70 ng/dL, though published reference intervals vary because most early population studies used immunoassays calibrated for male concentrations 2.

Menstrual-Cycle Phase and Testosterone Fluctuation

Testosterone in women is not static across the menstrual cycle. Ovarian theca cells produce androstenedione and testosterone in response to luteinizing hormone (LH), which surges at mid-cycle. Data from Sinha-Hikim et al. (N=60) using LC-MS/MS showed mean total testosterone of 19 ng/dL in the early follicular phase, rising to a peak of 42 ng/dL at ovulation, then falling back to 21 ng/dL in the mid-luteal phase 8. Some women reach 70 to 90 ng/dL at their LH surge peak.

This cycle-phase dependency has a direct clinical implication: a testosterone sample drawn on cycle day 1 to 3 will read substantially lower than one drawn on day 13 to 15. HealthRX recommends documenting cycle day on every female testosterone order and, when evaluating androgen deficiency, collecting the sample in the early-to-mid follicular phase (days 2 to 7) for consistency.

Postmenopausal Women

After menopause, ovarian testosterone production falls by roughly 50%, with adrenal androgen secretion accounting for most of the remaining output 9. Total testosterone in postmenopausal women generally runs 7 to 40 ng/dL in LC-MS/MS-based studies. SHBG often rises after menopause, particularly with oral estrogen therapy, which further suppresses free testosterone.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019), endorsed by the Endocrine Society and 10 other societies, states: "There is a moderate quality of evidence that testosterone therapy is effective for treating hypoactive sexual desire disorder in postmenopausal women" and recommends targeting the premenopausal physiological range rather than male reference intervals 10.

Female Androgen Excess: PCOS and Beyond

The upper boundary of the female reference range matters as much as the lower. Polycystic ovary syndrome (PCOS) affects 8 to 13% of reproductive-age women globally and is the most common cause of female androgen excess 11. The Rotterdam criteria require at least two of three features: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovary morphology. Total testosterone above 70 ng/dL by LC-MS/MS in a woman warrants further evaluation, including free testosterone, DHEA-S, and 17-hydroxyprogesterone to exclude congenital adrenal hyperplasia.

Testosterone in Transgender and Gender-Diverse Individuals

Reference ranges for cisgender men and women do not automatically apply to transgender individuals on gender-affirming hormone therapy. The Endocrine Society's 2017 clinical practice guideline for transgender persons recommends monitoring total testosterone with these phase-specific targets 12:

Transgender men (assigned female at birth, on testosterone therapy): Target total testosterone in the normal male range, typically 400 to 700 ng/dL, to achieve virilization while avoiding supraphysiologic levels. Many practitioners use the lower half of the male reference interval initially and titrate based on hematocrit, lipids, and symptom response.

Transgender women (assigned male at birth, on estrogen plus anti-androgen therapy): The goal is total testosterone in the female reference range (<50 ng/dL with most treatment regimens, ideally <30 ng/dL). This typically requires both an anti-androgen (spironolactone 100 to 200 mg/day, or bicalutamide 25 to 50 mg/day in some protocols) and estradiol. Orchiectomy eliminates most testicular testosterone production, after which anti-androgens may be reduced or discontinued.

Genital anatomy and hormone-producing tissue, not gender identity, determine which reference interval applies at any given point in treatment. HealthRX providers document surgical status and current therapy regimen before interpreting any testosterone result.

Why Total Testosterone Can Be Normal Yet Symptoms Persist

A man with a total testosterone of 420 ng/dL is technically within the normal range, but may still report fatigue, low libido, and reduced muscle recovery. Several mechanisms explain this disconnect.

SHBG and Bioavailable Fractions

SHBG binds testosterone tightly. Men with high SHBG (common in older age, hyperthyroidism, and liver disease) have elevated total testosterone but depressed free testosterone. In one cross-sectional analysis of 2,993 community-dwelling men, free testosterone correlated more strongly with symptom burden than total testosterone did, particularly for sexual function and energy 13. Free testosterone below the 2.5th percentile (approximately 50 pg/mL by equilibrium dialysis, or 6.5 ng/dL calculated) often justifies treatment even when total testosterone is mid-normal.

Androgen Receptor Sensitivity

CAG repeat length in the androgen receptor gene (AR gene on chromosome Xq11-12) modulates receptor sensitivity. Shorter CAG repeat sequences confer greater receptor activation per unit testosterone. A man with 15 CAG repeats may have adequate androgenic signaling at 400 ng/dL; a man with 28 repeats may require 600 ng/dL or higher for equivalent tissue effect 14. CAG repeat testing is not yet standard of care but is increasingly used in longevity and men's health practices.

Albumin and Protein-Binding Changes

Severe illness, nephrotic syndrome, and cirrhosis reduce albumin, which lowers total testosterone even when gonadal production is unchanged. In these settings, free testosterone by equilibrium dialysis is a more reliable marker of androgenic status than total testosterone alone.

Interpreting Total Testosterone in the Context of TRT Monitoring

For men already on testosterone replacement therapy, the timing and route of administration determine when to draw the monitoring sample.

Injection-Based TRT

Testosterone cypionate and testosterone enanthate (both intramuscular or subcutaneous, typically 50 to 200 mg every 7 to 14 days) produce large peak-to-trough swings. The Endocrine Society recommends drawing a mid-cycle trough sample (just before the next injection) to confirm the nadir stays above 300 ng/dL, and optionally a peak sample 24 to 72 hours post-injection to confirm the peak does not exceed 1,100 ng/dL 3. Weekly injections produce smaller swings than biweekly regimens and are preferred when mood or energy fluctuations are reported.

Topical and Transdermal TRT

Gels and creams (testosterone 1 to 1.62% gel, or compounded formulations) produce more stable levels but have variable absorption. For gels, draw the sample 2 to 4 hours after morning application for the approximate peak, or 12 to 24 hours after application for a rough average. Pellet implants (Testopel 75 mg per pellet, typically 6 to 12 pellets every 3 to 6 months) are monitored at 4 to 6 weeks post-insertion for the peak and again at weeks 10 to 12 for mid-cycle status.

Oral TRT

Testosterone undecanoate (Jatenzo 158 to 316 mg twice daily with food) became the first FDA-approved oral testosterone in 2019 15. Monitoring draws are done 4 to 6 hours after the morning dose, targeting a concentration of 400 to 800 ng/dL.

Common Pre-Analytical Errors That Distort Total Testosterone Results

Getting the number right starts before the blood draw. Several controllable variables shift total testosterone by 15 to 40%.

Timing and Fasting

Acute caloric restriction and prolonged fasting (over 24 hours) lower LH pulsatility and consequently suppress testosterone. A standard 8-hour overnight fast before an early-morning draw is recommended. Vigorous aerobic exercise within 12 hours of the draw may transiently raise testosterone by 15 to 20% in trained men, while overtraining syndrome depresses it chronically 16.

Acute Illness and Stress

Systemic illness, even a moderate respiratory infection, suppresses the hypothalamic-pituitary-gonadal (HPG) axis via inflammatory cytokines. Testosterone drawn during an acute illness is not representative of baseline status. HealthRX requires that men be in their habitual state of health for at least two weeks before a baseline draw.

Medication Interactions

Opioids suppress LH secretion and can reduce total testosterone by 50 to 90% in chronic users 17. Glucocorticoids suppress the HPG axis at the hypothalamic level. Ketoconazole and abiraterone block testicular and adrenal testosterone synthesis. All current medications must be documented before interpreting any testosterone result.

Age-Related Decline and When to Act

Not every man with low testosterone needs treatment. The decision to initiate TRT depends on the combination of consistently low morning testosterone levels (below 300 ng/dL on two separate draws), a symptom burden that scores above the threshold on a validated tool such as the ADAM questionnaire or the AMS scale, and the absence of a reversible cause such as obesity, sleep apnea, or medication-induced suppression.

In the T Trials, men aged 65 and older with baseline testosterone below 275 ng/dL showed statistically significant improvements in sexual activity (P<0.001), walking distance (P = 0.003), and bone mineral density at the spine (P<0.001) at 12 months after TRT compared to placebo 7. Benefits were most pronounced in men whose on-treatment testosterone reached 500 ng/dL or above.

Weight loss alone can raise testosterone meaningfully in obese men. A 10% reduction in body weight corresponds to approximately a 50 to 60 ng/dL rise in total testosterone in men with obesity-related hypogonadism 18. Sleep apnea treatment with continuous positive airway pressure (CPAP) can raise testosterone by 60 to 100 ng/dL in men whose hypogonadism is predominantly sleep-disruption-driven 19.

Female Testosterone Optimization: What the Evidence Supports

For women, testosterone therapy is currently FDA-approved only for the androgen phase of gender-affirming care, not for androgen deficiency in cisgender women. Despite this regulatory gap, off-label use of low-dose testosterone in postmenopausal women with hypoactive sexual desire disorder is supported by three systematic reviews and meta-analyses.

A 2019 Cochrane-affiliated network meta-analysis (36 randomized trials, N=8,480 postmenopausal women) found that transdermal testosterone at physiological doses (targeting serum levels in the premenopausal female range) produced a statistically significant improvement in satisfying sexual events per month compared to placebo (mean difference 0.85 events per 28-day period, 95% CI 0.52 to 1.18) 20. No increase in cardiovascular events or breast cancer was observed at trial durations up to 24 months, though the authors noted that long-term data beyond two years are limited.

The Global Consensus Position Statement (2019) concludes: "Testosterone therapy for women should achieve total testosterone concentrations in the physiological premenopausal range (15 to 70 ng/dL). Supraphysiological concentrations should be avoided" 10.

HealthRX monitors female patients on testosterone therapy at 3 months after initiation and every 6 months thereafter, using LC-MS/MS-based total testosterone plus free testosterone by equilibrium dialysis.

How HealthRX Uses Total Testosterone in Clinical Decision-Making

The HealthRX lab panel for hormone evaluation always pairs total testosterone with SHBG, LH, FSH, and estradiol. Total testosterone in isolation answers only part of the clinical question.

For male patients, the diagnostic algorithm works as follows: if total testosterone is below 300 ng/dL on two morning draws, LH and FSH differentiate primary hypogonadism (high gonadotropins, testicular failure) from secondary hypogonadism (low or normal gonadotropins, pituitary or hypothalamic cause). Secondary hypogonadism with a structural pituitary abnormality requires MRI of the sella before TRT is started.

For female patients below the expected range, the differential includes hypothalamic amenorrhea, hypopituitarism, adrenal insufficiency, and post-oophorectomy status. DHEA-S helps identify adrenal contribution, and a provocative ACTH stimulation test may be ordered if adrenal insufficiency is suspected.

The HealthRX "Total T Triage Framework" categorizes results into four action tiers:

1. Total T >300 ng/dL (men) or >15 ng/dL (women) with no symptoms: Recheck in 12 months; optimize lifestyle factors.
2. Total T borderline low with symptoms: Confirm with second morning draw, add free T, SHBG, LH, FSH. Address reversible causes first.
3. Total T confirmed low (<300 ng/dL men, <15 ng/dL women) with symptoms and no reversible cause: Discuss therapy initiation; document shared decision-making.
4. Total T below 150 ng/dL (men) or any sign of adrenal crisis (women): Urgent workup; endocrinology referral within two weeks.